{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:49:12Z","timestamp":1781005752870,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.lungcan.2019.10.016","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T11:35:20Z","timestamp":1571398520000},"page":"89-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203"],"prefix":"10.1016","volume":"139","author":[{"given":"Yoko","family":"Tsukita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-683X","authenticated-orcid":false,"given":"Akira","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-0210","authenticated-orcid":false,"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.10.016_bib0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database","volume":"9","author":"Ruffini","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0010","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","article-title":"Systemic treatments for thymoma and thymic carcinoma: A systematic review","volume":"126","author":"Berghmans","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.10.016_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0025","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of Everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0030","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","article-title":"A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma","volume":"13","author":"Gbolahan","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0040","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","author":"Cho","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0045","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/annonc\/mdx419","article-title":"Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)","volume":"28","author":"Nokihara","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0050","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2010.09.004","article-title":"S-1 is an active anticancer agent for advanced thymic carcinoma","volume":"70","author":"Okuma","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2019.10.016_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1898","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.lungcan.2019.10.016_bib0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes","volume":"10","author":"Marx","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0065","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.14694\/EdBook_AM.2014.34.e367","article-title":"Systemic treatment of advanced thymic malignancies","author":"Kelly","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.lungcan.2019.10.016_bib0070","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/JTO.0000000000000362","article-title":"Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer Group Study 0803","volume":"9","author":"Inoue","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.resinv.2016.10.008","article-title":"Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1","volume":"55","author":"Kakiuchi","year":"2017","journal-title":"Respir. Investig."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10147-010-0034-0","article-title":"Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer","volume":"15","author":"Ono","year":"2010","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3892\/ol_00000027","article-title":"Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens","volume":"1","author":"Takakuwa","year":"2010","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00280-017-3432-4","article-title":"A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)","volume":"80","author":"Ikezawa","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0095","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jjco\/hyw062","article-title":"Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701","volume":"46","author":"Soh","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/sj.bjc.6602804","article-title":"Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer","volume":"93","author":"Tsukuda","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.10.016_bib0105","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3892\/mco.2015.500","article-title":"Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S-1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest","volume":"3","author":"Yamatsuji","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.10.016_bib0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.resinv.2017.09.003","article-title":"Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer","volume":"56","author":"Goto","year":"2018","journal-title":"Respir. Investig."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021930697X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021930697X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:34:45Z","timestamp":1759235685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950021930697X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":22,"alternative-id":["S016950021930697X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.10.016","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}